"Total CroFab and Anavip Antivenom Vial Administration in US Rattlesnake Envenomations: 2019-2021"
View an analysis of the American College of Medical Toxicology’s (ACMT) Toxicology Investigators Consortium (ToxIC) North American Snakebite Registry (NASBR) comparing antivenoms for crotalid (pit viper) envenomations from 2019 to 2021, which shows treatment with CroFab required fewer total vials and fewer administrations than a competitor.
"The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial"
Clinical trial demonstrating how treatment with FabAV can reduce limb disability.
"Early Administration of Fab Antivenom Resulted in Faster Limb Recovery in Copperhead Snake Envenomation Patients"
Secondary analysis of a clinical trial demonstrating that patients treated with FabAV earlier had a significantly shorter time to full recovery than those treated late (median time: 17 versus 28 days, P=0.025).
"Antivenom Treatment Is Associated With Fewer Patients Using Opioids After Copperhead Envenomation"
Secondary analysis of a clinical trial demonstrating that the proportion of patients using opioids for pain related to envenomation was smaller in the FabAV treatment group at all follow-up time points, and that the odds ratio of using opioids after hospital discharge among those who received placebo was 5.67 times that of those who received FabAV.
"Acute Adverse Events Associated With the Administration of Crotalidae Polyvalent Immune Fab Antivenom Within the North American Snake Bite Registry"
A retrospective study of 373 patients finds 2.7% incidence of adverse reactions overall, and a 1% incidence of severe adverse reactions.
"Incidence of Allergic Reactions to Crotalidae Polyvalent Immune Fab"
Retrospective study of 1340 CroFab patients finds low incidence (1.4%) of acute hypersensitivity reactions.
"Incidence of Immediate Hypersensitivity Reactions and Serum Sickness Following Administration of Crotalidae Polyvalent Immune Fab Antivenom: A Meta-analysis"
Systematic literature review and meta-analysis of immediate hypersensitivity reactions and serum sickness from FabAV.
"Medically Significant Late Bleeding After Treated Crotaline Envenomation: A Systematic Review"
Study to estimate the proportion of patients with crotaline snake envenomation, treated with Crotalidae polyvalent immune Fab (ovine) antivenom, who develop medically significant late bleeding.
"Affinity-Purified, Mixed Monospecific Crotalid Antivenom Ovine Fab for the Treatment of Crotalid Venom Poisoning"
First premarketing clinical study of CroFab, TAb001, to test the efficacy and safety of a new antivenom, affinity-purified, mixed monospecific crotalid antivenom ovine Fab in human subjects with minimal or moderate crotalid envenomation.
"A Randomized Multicenter Trial of Crotaline Polyvalent Immune Fab (Ovine) Antivenom for the Treatment of Crotaline Snakebite in the United States"
The second clinical trial of CroFab, TAb002, and the first randomized clinical trial of antivenom in the US showing efficacy and safety of CroFab in crotaline envenomation.
1. CroFab®. Prescribing information. BTG International Inc.; August 2018.